SEB Asset Management AB Makes New Investment in Natera, Inc. $NTRA

SEB Asset Management AB purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the first quarter, Holdings Channel reports. The institutional investor purchased 85,074 shares of the medical research company’s stock, valued at approximately $17,014,000.

Several other hedge funds and other institutional investors have also made changes to their positions in NTRA. Integrated Wealth Concepts LLC grew its position in shares of Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,847 shares in the last quarter. Focus Partners Wealth raised its holdings in Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in Natera in the second quarter valued at approximately $298,000. Finally, WINTON GROUP Ltd purchased a new position in Natera in the second quarter worth approximately $558,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insiders Place Their Bets

In other news, Director Rowan E. Chapman sold 2,964 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total transaction of $642,535.92. Following the completion of the sale, the director owned 3,124 shares in the company, valued at approximately $677,220.72. This represents a 48.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the transaction, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. This trade represents a 27.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 178,872 shares of company stock valued at $39,627,696. 5.05% of the stock is owned by insiders.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $262.63 on Tuesday. The stock has a market cap of $37.61 billion, a P/E ratio of -161.12 and a beta of 1.51. The firm has a fifty day moving average price of $235.24 and a 200 day moving average price of $220.56. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $288.04.

Analyst Ratings Changes

A number of brokerages have commented on NTRA. JPMorgan Chase & Co. increased their price objective on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Piper Sandler reaffirmed an “overweight” rating and set a $249.00 price objective on shares of Natera in a research report on Tuesday, May 12th. BTIG Research set a $275.00 target price on shares of Natera and gave the stock a “buy” rating in a research note on Wednesday, June 24th. William Blair assumed coverage on shares of Natera in a research note on Tuesday, April 14th. They set an “outperform” rating for the company. Finally, UBS Group set a $260.00 target price on Natera in a report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.